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ABSTRACT
Malignant gliomas are among the most frequent and aggressive cerebral tumors, 
characterized by high proliferative and invasive indexes. Standard therapy for patients, 
after surgery and radiotherapy, consists of temozolomide (TMZ), a methylating 
agent that blocks tumor cell proliferation. Currently, there are no therapies aimed at 
reducing tumor cell invasion. Ion channels are candidate molecular targets involved 
in glioma cell migration and infiltration into the brain parenchyma. In this paper we 
demonstrate that: i) blockade of the calcium-activated potassium channel KCa3.1 with 
TRAM-34 has co-adjuvant effects with TMZ, reducing GL261 glioma cell migration, 
invasion and colony forming activity, increasing apoptosis, and forcing cells to pass 
the G2/M cell cycle phase, likely through cdc2 de-phosphorylation; ii) KCa3.1 silencing 
potentiates the inhibitory effect of TMZ on glioma cell viability; iii) the combination of 
TMZ/TRAM-34 attenuates the toxic effects of glioma conditioned medium on neuronal 
cultures, through a microglia dependent mechanism since the effect is abolished 
by clodronate-induced microglia killing; iv) TMZ/TRAM-34 co-treatment increases 
the number of apoptotic tumor cells, and the mean survival time in a syngeneic 
mouse glioma model (C57BL6 mice implanted with GL261 cells); v) TMZ/TRAM-34 
co-treatment reduces cell viability of GBM cells and cancer stem cells (CSC) freshly 
isolated from patients.
Taken together, these data suggest a new therapeutic approach for malignant 
glioma, targeting both glioma cell proliferating and migration, and demonstrate 
that TMZ/TRAM-34 co-treatment affects both glioma cells and infiltrating microglia, 
resulting in an overall reduction of tumor cell progression.
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INTRODUCTION
Malignant gliomas (III grade astrocytoma and 
IV grade glioblastoma (GBM) according to the WHO 
classification) are the most diffuse and aggressive 
neoplasia of the central nervous system, characterized 
by high proliferation, angiogenesis, suppression of 
immune responses and invasiveness. Despite current 
treatments consisting of surgery followed by adjuvant 
radiotherapy and chemotherapy with the methylating 
agent temozolomide (TMZ), GBM patients display a 
median overall survival of only 14.6 months [1]. Tumors 
invariably recur, mainly due to residual cancer stem cells 
(CSC) [2] and to malignant cells escaping surgery and 
infiltrating healthy parenchyma. Even though significant 
advances in cancer molecular targeting have been made, 
several promising preclinical results revealed poor 
translatability (www.clinicaltrial.gov). TRAM-34 is a high 
affinity blocker of KCa3.1, exhibiting good selectivity 
for these channels [3]. In the healthy adult brain, KCa3.1 
channels are primarily expressed in microglia [4] and 
vascular endothelial cells [5] and are mostly undetectable 
in other cell populations [6]. In contrast, in GBM, KCa3.1 
channels are also functionally expressed by tumor cells 
[7–9]. The REepository of Molecular BRAin Neoplasia 
DaTa (REMBRANDT) database identified the gene 
KCNN4, which encodes for KCa3.1, as being over-
expressed in 32% of glioma patients and correlating 
with significant shortened survival [10]. We and others 
recently demonstrated the involvement of KCa3.1 
channels in GBM cell spreading in healthy parenchyma 
[10, 11]. Considering that malignant gliomas consist of 
proliferating and migrating cells [12–14], with the last 
often exhibiting reduced sensitivity to anti-proliferative 
or pro-apoptotic drugs [15, 16], we wondered whether 
KCa3.1 inhibition or silencing could potentiate the 
effects of standard chemotherapy with TMZ. TMZ is a 
cytotoxic imidazotetrazine that leads to the formation 
of O6- methylguanine, which mismatches with thymine 
in subsequent DNA replication cycles, with effects 
on several cellular functions, such as apoptosis [17], 
autophagy [18], mitotic catastrophe and senescence-like 
events [17]. In most cells, TMZ produces cell cycle arrest 
in the G2/M phase, through the activation of the DNA 
damage checkpoint pathways ATM/ATR-Chk1/2/cdc25C 
[19, 17]. G2/M check point activation requires cyclin 
B binding and phosphorylation of cdc2 at Thr14 and 
Tyr15 [20, 21]. Forcing cells to escape this check point 
might induce mitotic catastrophe and cell senescence 
[17, 22–24].
TRAM-34 is safe and well tolerated in various 
animal models [25]; it crosses the blood brain barrier, 
reaching biologically active concentrations in the 
brain parenchyma [11, 26]. In this paper we co-treated 
GBM cells, CSC acutely isolated from patients, and 
glioma cell lines with TMZ and TRAM-34, describing 
co-adjuvant effects on different parameters like cell 
invasion, proliferation, and apoptosis, as well as 
viability. TMZ treatment of KCa3.1 silenced glioma 
cells reproduced several effects of TRAM-34/TMZ co-
treatment. TRAM-34 and TMZ co-treatment of glioma 
bearing mice also increased the frequency of apoptotic 
cells and significantly increased the mean survival time.
RESULTS
Combination of TRAM-34 and TMZ reduces 
migration and invasion of GL261 cells
To determine whether the basal migration and 
invasion across extracellular matrix of GL261 cells were 
modulated by KCa3.1 channel inhibition with TRAM-34, 
by TMZ, or both, wound healing and transwell matrigel 
invasion assays were performed. TMZ and TRAM-34 
concentrations were chosen as specified in the Methods. 
Figure 1A shows cell movement in a wound healing assay 
upon drug treatment: after 48 h, untreated cells covered 
45% of wounded area, similarly to TMZ treated cells. 
TRAM-34 reduced the wound healing ability (to 22% ± 
5) and the combination TMZ/TRAM-34 further reduced 
basal cell migration (to 12% ± 1). Figure 1B shows that 
TRAM-34 and TMZ treatment (48 h) significantly reduced 
GL261 cell invasion through a Matrigel layer, and that the 
co-treatment resulted in a stronger reduction.
To investigate whether the effect of TMZ on cell 
movement could be due to a direct effect on KCa3.1 
channel activity, patch clamp recording of GL261 cells 
was performed in the presence of TMZ. We observed 
that KCa3.1 channels were functional in GL261 and their 
activation was not affected by TMZ (Figure 1C-1D). 
Conversely, KCa3.1 activity did not modify the membrane 
resting potential of these cells, which was -38.7 ± 4.3 mV 
in untreated and -38.5 ± 6.3 mV in TRAM-34 treated cells 
(n= 26).
TRAM-34 and TMZ co-treatment reduces 
colony formation and proliferation of GL261 
cells
We wondered whether combined treatment with 
TRAM-34 and TMZ of glioma cells could reduce tumor 
cell proliferation more efficiently than TMZ alone. 
Towards this aim, the effect of TRAM-34 and TMZ was 
tested on clonogenicity and proliferation of GL261 using 
a colony forming assay and performing a growth curve 
staining cells with crystal violet. As shown in Figure 2A, 
TRAM-34 alone had a smaller but significant effect, in 
comparison with TMZ, on the number of colonies, as 
expected from the known TMZ sensitivity of GL261 cells 
[27]. Interestingly, combined TMZ/TRAM-34 treatment 
further reduced colony growth. With the same method, 
we also tested the proliferation of GL261 cells treated 
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with TMZ and TRAM-34 or both. As shown in Figure 
2B, all treatments reduced cell growth, but again the 
combined TMZ/TRAM-34 treatment further decreased 
cell proliferation, with induction of cell death at 96 h. Data 
on cell proliferation were also confirmed using a MTT 
assay (Supplementary Figure S1). These results indicate 
an increased cell sensitization to TMZ upon KCa3.1 
inhibition and prompted us to investigate the effect on 
GL261 cell cycle upon single or combined drug treatments. 
Cell cycle distribution were investigated by FACS and 
western blot analyses: Figure 2C shows that GL261 cells 
treated with TRAM-34 have an increased frequency in 
G0/G1, further confirmed by a decreased expression of 
cyclin D1 (Supplementary Figure S2). TMZ treatment 
induced cell arrest in G2/M phase, as already observed in 
other cells [22, 23], while the combined TMZ/TRAM-34 
treatment overrode the effect of TMZ on cell cycle arrest. 
Since cdc2 activation by phosphorylation on Tyr15 blocks 
cells from entering in mitosis [20], we analyzed the effect 
of TMZ, TRAM-34 or both on cdc2 phosphorylation. 
Figure 2D shows that, upon TMZ treatment, cdc2 
phosphorylation increased, while TRAM-34 co-treatment 
blocked protein activation. Of note, TRAM34 alone was 
ineffective on cdc2 phosphorylation. To further validate 
the effect of KCa3.1 block on cdc2 modulation, GL261 
cells were treated with TRAM-34 in the presence of a 
specific phosphatase cdc25 inhibitor, NSC95397. Under 
these conditions, TRAM-34 did not block TMZ effect 
(Figure 2D), demonstrating that cdc25C is involved. In 
contrast, a specific KCa3.1 channel activator (SKA-31) 
increased cdc2 phosphorylation and SKA-31/TMZ co-
treatment further increased it (Figure 2E), indicating that 
Figure 1: TRAM-34/TMZ treatment reduces basal cell migration and invasion of GL261 cells. A. GL261 cells were treated 
with vehicle (control, C), TMZ, TRAM-34 or both (T+T) for 48 h and assayed for migration. The wound healing was analyzed using 
ImageJ software and data are expressed as [1- (empty area at 48 h/ empty area at 0 h)] x100, where the empty area at 0 h is indicated by 
the dotted parallel lines and the empty area at 48 h is comprised between the dotted curved lines. *p<0.05; ***p<0.001 vs C; °° p<0.01 vs 
TMZ n=4, One-Way ANOVA, Student-Newman-Keuls post-test. Representative picture of wound healing assay is shown on the right (4X 
magnification, bar = 100 μm). B. GL261 cells were treated as in A and plated on Matrigel film for 48 h; ***p<0.001 vs C; °°° p<0.001 vs 
TMZ n=4, One-Way ANOVA, Student-Newman-Keuls post-test. C. Time course of the effect of TRAM-34 (2.5 μM) on current evoked 
in GL261 cells (n= 12) by repeated voltage ramps (from -130 mV to + 50 mV, holding potential -70 mV). Acute application of TRAM-34 
revealed the functional expression of KCa3.1 channels. Typical current trace in response to repeated ramps is shown in the inset. D. Time 
course of the effect of TMZ (30 μM) application alone and in co-application with TRAM-34 (2.5 μM) on current evoked in GL261 cells 
(n= 7) by repeated voltage ramps.
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Figure 2: TRAM-34/TMZ treatment reduces clonogenicity and growth of GL261 cells and alters cell cycle. A. GL261 
cells were treated with vehicle (control, C), TMZ, TRAM-34 or both (T+T) for 24 h. Colonies grown were counted at 14 days. Data are 
expressed as % of C, *p<0.05, **p<0.01 and ***p<0.001 vs C; ° p<0.05 vs TMZ n=4 by One-Way ANOVA, Student-Newman-Keuls 
post-test. Right, representative picture of a colony forming assay. B. Growth curve of GL261 cells treated as in A for the indicated time 
points. The results are expressed as function of the optical density (OD) at 590 nm.*p<0.05vs C; ° p<0.05 vs TMZ n=3, One-Way ANOVA, 
Student-Newman-Keuls post-test. C. GL261 cells were treated as in A for 72 h and cell cycle analysis was performed by flow cytometry. 
Representative experiment on the left shows % cells in different phases of the cell cycle. The mean percentage of cells in G2/M phase with 
the different treatments is shown on the right. *p<0.05 and ***p<0.001 vs C; ° p<0.05 and °°° p<0.001 vs TMZ n=3 by One-Way ANOVA, 
Student-Newman-Keuls post-test. D. GL261 cells were treated as in A in absence or presence of NSC-95397(60 nM) for 48 h, lysed and 
analyzed by Western Blot for cdc2 phosphorylation. Data are shown as p-cdc2/cdc2 ratio; *p <0,05vs C n = 4, One-Way ANOVA, Student-
Newman-Keuls post-test. Right, representative blot. E. GL261 cells were treated with vehicle (control, C), SKA-31 (250 nM) or SKA-31 
+ TMZ (30 μM) for 48 h, lysed and analyzed by Western Blot for cdc2 phosphorylation. Data are shown as p-cdc2/cdc2 ratio; ***p <0,001 
vs C n = 4,°° p <0,01 vs SKA-31. One-Way ANOVA, Student-Newman-Keuls post-test. Right, representative blot.
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channel function might sustain cell cycle arrest also 
upon TMZ-induced DNA damage. Taken together, these 
data demonstrate that KCa3.1 blockade with TRAM-34 
counteracts the effect of TMZ on cell cycle arrest and 
further reduces tumor cell proliferation.
TRAM-34/TMZ co-treatment increases 
apoptosis in glioma cells
To test if the effect of TRAM-34 and TMZ treatment 
on cell cycle could result in tumor cell apoptosis, glioma 
cells were treated with TRAM-34, TMZ or both and 
stained with AnnexinV/PI. The data in Figure 3 show that, 
at 96 h, TMZ/TRAM-34 significantly increased the number 
of GL261 apoptotic cells in comparison with TRAM-34 
and TMZ alone. TMZ/TRAM-34 treatment also increased 
apoptosis in other glioma cells like the human U87MG and 
the patient-derived GBM (GBM18), suggesting common 
effects on apoptotic pathways. As already shown for 
GL261 cells, we found functional expression of KCa3.1 
channels by patch clamp recordings also in the human 
GBM cell tested (Supplementary Figure S3).
TMZ treatment decreased viability of KCa3.1 
silenced glioma cells
To verify that the effect of TRAM-34 was due to 
its specific inhibition of KCa3.1 activity, GL261, U87MG 
and primary glioblastoma cells (GBM18) were silenced 
for KCa3.1 expression with IPTG-inducible shRNA 
constructs, treated with TMZ and analyzed for viability. 
The efficacy of silencing was confirmed by RT-PCR, 
and shown in Figure 4A, with reductions of 35.3±1.7% 
(GL261), 47.8±8.9% (U87MG) and 50.0±7.5% (GBM18) 
of KCNN4 mRNA upon IPTG induction. GL261shRNA 
cells were also tested for KCa3.1 current: patch clamp 
recordings performed on vehicle- and IPTG-induced 
GL261 cells demonstrated that KCa3.1 currents were 
strongly reduced in these cells (Figure 4B), thus supporting 
the efficacy of channel silencing. TMZ treatment (96h) of 
silenced cells significantly reduced cell viability, similarly 
to what was observed for TRAM-34/TMZ co-treatment 
(Figure 4C). Note that in GBM18shRNA, only TMZ/
TRAM-34 co-treatment reduced cell viability, comparably 
to what was reported for Annexin V/PI staining (Figure 3).
TRAM-34 reduces neuronal death induced by 
GL261 cells acting through microglia
To investigate whether KCa3.1 inhibition also 
affects the brain tumor microenvironment, we co-
cultured primary hippocampal cells (60–70% neurons, 
30-35% astrocytes, 4–8% microglia) with GL261 in 
the presence or absence of TRAM-34, TMZ or both. As 
expected, under these conditions, hippocampal neurons 
died from excitotoxicity [28] induced by glutamate 
released by GL261 (293 ± 2μM in the medium after 24 
h in culture). TRAM-34 and TMZ/TRAM-34 treatments 
significantly reduced neuronal death, while TMZ 
alone was ineffective (Figure 5). Neuroprotection was 
measured with two different independent tests with similar 
results (data reported refer to the cell lysis protocol, see 
methods). Since KCa3.1 channels are also expressed by 
microglia, we evaluated the microglia involvement in 
the neuroprotective effect of TRAM-34 by their specific 
depletion with clodronate-containing liposomes. Results 
shown in Figure 5 indicate that the absence of microglia 
abolished the neuroprotective effects of TRAM-34, 
highlighting a key intermediate role for this cell population 
in reducing neuronal toxicity.
Figure 3: TMZ/TRAM-34 treatment increases apoptosis in murine and human malignant glioma cells. GL261, U87MG 
and GBM18 cells were treated with vehicle (control, C), TMZ, TRAM-34 or both (T+T) for 96 h. Cell apoptosis was detected by flow 
cytometry; data represent the mean value of Annexin V positive plus Annexin V/PI positive cells expressed as percentage of total cells. 
*p<0.05 and ***p<0.001 vs C; ° p<0.05, °° p<0.01 and °°° p<0.001 vs TMZ n=3 by One-Way ANOVA, Student-Newman-Keuls post-test.
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TRAM-34/TMZ co-treatment increases survival 
in GL261 bearing-mice, reduces tumor volume 
and increases apoptosis
The results obtained in vitro prompted us to 
investigate the possible effects of TRAM-34 and its 
combination with TMZ in a syngeneic glioma mouse 
model. Figure 6A illustrates the survival of mice-injected 
with GL261 cells upon TRAM-34, TMZ or TMZ/TRAM-
34 treatment. All conditions significantly increased mice 
survival but, again, the combination of TRAM-34 and 
TMZ was more effective in term of mean survival time 
(76± 7 days) in comparison with TMZ (55 ± 6days) and 
TRAM-34 (48 ± 8days) alone (survival time of control 
animals was 31± 2 days). Beneficial effects of treatments 
were already observed after 21 days as decrease in tumor 
volume (Figure 6B, upper panel) and increase of body 
weight (Figure 6B, lower panel). These mice also had a 
Figure 4: KCa3.1 silencing and TMZ treatment reduce glioma cell viability. A. GL261, U87MG and GBM18 cells were 
infected with IPTG-inducible shRNA construct to silence KCa3.1 channel (GL261shRNA, U87MGshRNA and GBM18shRNA). Cells 
were induced (+IPTG) or not (-IPTG) and assayed for the expression of channel mRNA (KCNN4) by RT-PCR. Data are expressed as fold 
increase vs -IPTG. *p<0.05 and **p<0.01 vs –IPTG. n=4 by One-Way ANOVA, Student-Newman-Keuls post-test. B. Bar chart showing 
average KCa3.1 current amplitude, obtained as TRAM-34 (2.5 μM) sensitive current, in GL261shRNA cells without (n=7) and with IPTG 
induction (n=8), by repeated voltage ramps (from -130 mV to + 50 mV, holding potential -70 mV). Right, typical current trace in response 
to repeated ramps in control (black trace) and in induced GL261shRNA (grey trace). C. GL261shRNA, U87MGshRNA and GBM18shRNA 
cells were treated with vehicle (C) or TMZ for 96 h and tested for cell viability by MTT assay. Cell viability is expressed as a function 
of optical density (OD). *p<0.05, **p<0.01 and ***p<0.001 vs C; ° p<0.05 vs TMZ n=4 by One-Way ANOVA, Student-Newman-Keuls 
post-test.
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higher proportion of apoptotic cells in the tumor mass: 
Figure 6C shows that GL261-RFP-bearing mice treated 
with TMZ/TRAM-34 had increased Annexin-V positive 
cells (green) in the tumor core (red cells) in comparison 
with vehicle-treated or TRAM-34 and TMZ treated mice 
after 21 days. The effects on tumor volume and apoptosis 
could underlie the increase in survival observed in TMZ/
TRAM-34 treated mice.
TRAM-34/TMZ treatment decreases cell 
viability of GBM cells and CSC
To address the potential validity of a future clinical 
use of a KCa3.1 blocker such as TRAM-34 combined with 
TMZ, we tested the effect of the combination on GBM 
cells acutely obtained from fourteen patients and on CSCs 
obtained from one patient. Table 1 shows cell viability, 
measured by MTT assay, upon 5 day treatment with 
TMZ or in combination with TRAM-34 in comparison 
with untreated cells (C). At least in seven samples 
(GBM14, GBM19, GBM29, GBM33, GBM55, GBM109, 
GBM111), TMZ/TRAM-34 treatment significantly 
reduced cell viability in comparison with TMZ alone, 
with more scattered results in the others. DNA synthesis, 
measured as [3H]-thymidine incorporation, was tested 
in enriched-CSC cultures, maintained as neurospheres 
(Figure 7A). CSC were preliminary assayed for CD133 
expression, and KCa3.1 channel expression, showing 
20% of CD133+ cells in the preparation (Supplementary 
Figure S4). These cells had TRAM-34 sensitive KCa3.1 
currents (Figure 7B). Following four day treatment with 
TMZ, TRAM-34 or both, we observed that only TRAM-
34/TMZ co-treatment significantly reduced DNA synthesis 
(Figure 7C).
Taken together these data confirm the ability of 
TRAM-34 to sensitize cells obtained from GBM patients 
to TMZ cytotoxicity. The reason for the failure to increase 
TMZ cytotoxicity in about 50% of samples remains to be 
established but could be due to individual variability, also 
for KCa3.1 over-expression [10].
DISCUSSION
New therapeutic strategies aiming to fight both 
migrating and proliferating glioma cells are necessary to 
effectively counteract GBM progression. In the present 
study we describe that glioma-bearing mice, when co-
treated with TRAM-34 and TMZ, significantly increase 
the mean survival time in comparison with single-drug 
treatments. The beneficial effect of TMZ/TRAM-34 co-
treatment in glioma bearing mice can be explained by 
the following effects observed in vitro: i) reduced glioma 
cell migration and invasion; ii) reduced colony forming 
ability, glioma proliferation rate and apoptotic index; iii) 
alterations of cell cycle progression; iv) protection from 
glioma-induced neuronal cell death. Similar results were 
obtained with cells acutely obtained from patients and in 
GBM- enriched CSC, since TMZ/TRAM-34 also reduced 
their viability.
Figure 5: Microglia cells mediate TRAM-34-induced neuroprotection against GBM toxicity. Hippocampal cultures, treated 
with empty (grey bars) or clodronate-filled liposomes (white bars) were co-cultured or not (C) with GL261 cells and treated with vehicle, 
TMZ, TRAM-34 or both (T+T). Results are expressed as percentage of cell survival, taking C as 100%. ***p<0.001; # p<0.05; § p<0.05; 
°°° p<0.001; n=3, One-Way ANOVA, Student-Newman-Keuls post-test.
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GBM recurrence in TMZ treated patients is often 
due to diffuse glioma invasiveness of cerebral parenchyma. 
Recent data suggest key roles for ion channels in mediating 
tumor cell migration [29], with direct involvement of 
calcium-activated potassium channels. We and others 
have recently demonstrated that KCa3.1 inhibition, 
or silencing, reduces tumor cell infiltration in the brain 
parenchyma in experimental mouse models of the disease 
[10, 11], thus supporting previous in vitro findings [30]. 
We now demonstrated that KCa3.1 inhibition or silencing 
significantly enhances the anti-proliferative effects of the 
alkylating agent TMZ, increasing the number of apoptotic 
cells and reducing cell viability, suggesting KCa3.1 as a 
key therapeutic target for glioma. We demonstrate that the 
combined treatment with TMZ/TRAM-34 reduces tumor 
cell infiltration and migration more potently than single 
treatment. We also show that TMZ/TRAM-34 decreased 
glioma cell proliferation, reducing cell survival and 
clonal ability. These effects are likely due to the increased 
apoptosis, induced through decreased phosphorylation 
Figure 6: TRAM-34 and TMZ/TRAM-34 treatment increases survival of GL261-bearing mice. A. Kaplan-Meier survival 
curves of glioma bearing mice treated with vehicle (control, C), TRAM-34, TMZ or both (T+T) (n=8-11, log-rank test results are shown in 
the inset). B. Glioma bearing mice, 21 days after glioma cell inoculation, were analyzed for tumor volumes (upper panel; * p<0.05 vs C; 
n= 7, One-Way ANOVA, Student-Newman Keuls post-test) and mouse weight (lower panel; *p<0.05 vs C; n=10-11, One-Way ANOVA, 
Student-Newman-Keuls post-test). C. Glioma bearing mice, 21 days after glioma cell inoculation, were analyzed for apoptosis. Brain slices 
(tumor core) obtained from mice injected with GL261-RFP cells (red) treated with vehicle (control, C), TRAM-34, TMZ or both (T+T) 
analyzed for immunofluorescence of Annexin V (green, bar =10 μm); results are expressed as arbitrary units obtained by the ratio between 
Annexin-V positive area and tumor area analyzed; * p<0.05 vs C; ° p<0.05 vs TMZ n= 3, One-Way ANOVA, Student-Newman Keuls 
post-test.
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level of proteins regulating cell cycle, like cdc2. Activation 
of cdc2 is regulated by a balance between kinases (cdk) 
and phosphatase (cdc25C) activity [31]. It is known that 
TMZ and other DNA-damaging agents inactivate cdc25C, 
arresting cells in G2, where cells check and repair possible 
DNA copy errors [17, 32]. Ion channels have often been 
associated with cell cycle progression through their 
involvement in the shape changes required for cell division 
[33–35]. We show that TMZ/TRAM-34 co-treatment 
forces cells to exit the G2 checkpoint and to move 
forward the G0/G1 phases, a process that induces mitotic 
catastrophe, cell senescence, and apoptotic death [22]. We 
observed a significant increase of apoptotic, Annexin V/
PI positive cells upon TMZ/TRAM-34 treatment, both in 
vivo, in glioma injected mice and in vitro, in glioma cell 
lines. Other molecules involved in cell cycle regulation, 
such as 7-hydroxystaurosporine, indolocarbazole inhibitor 
(SB-218078) and resveratrol, oppose to TMZ-induced 
cell arrest in G2 phase [17, 23, 24]. KCa3.1 in particular 
is required for cell cycle transition to the S phase and 
entry into G2/M, in different cancer cells [36, 37], and 
is involved in irradiation-induced cell accumulation in 
G2/M [38]. We demonstrated that cdc25C is a possible 
intermediate of the effect of TMZ/TRAM-34 on glioma 
cell death [17].
Data obtained in GBM cell lines were in part 
confirmed in human tumor cells obtained from patients. 
In these cells we observed that TMZ/TRAM-34 treatment 
significantly reduced cell viability in comparison with 
TMZ-treated cells in 7 out of 14 specimens. In addition, 
we observed that TMZ/TRAM-34 treatment significantly 
reduced proliferation of CSC obtained from one GBM 
patient, further validating this therapeutic approach.
It is known that microglia and macrophages invading 
GBM play key roles in tumor progression, representing 
the largest population of tumor-infiltrating cells [39]. We 
have previously shown that KCa3.1 inhibition reduced 
astrogliosis and microglia activation in glioma bearing 
mice [11] and reduces microglia activation and infarct size, 
increasing neuronal survival in a mouse model of ischemic 
Table 1: Effect of TRAM-34 and TMZ treatment on the viability of GBM cells from patients
 
 
CELL VIABILITY (% of C)
TMZ T+T
GBM9 105 ± 3 108 ± 2
GBM14 102 ± 5   85 ± 2 # *
GBM19 102 ± 2    89 ± 2 ## *
GBM20   92 ± 3*   90 ± 1*
GBM29 102 ± 3    88 ± 2## *
GBM33   78 ± 3 **    71 ± 1# **
GBM44  97 ± 5   112 ± 2# *
GBM55  94 ± 1    78 ± 1 ### **
GBM73  85 ± 1**  111 ± 4 ##
GBM107 103 ± 2  119 ± 8 #
GBM109 107 ± 2   94 ± 1 ###
GBM110  94 ± 5   88 ± 1*
GBM111  93 ± 3    82 ± 3 ## *
GBM112 103 ± 4 100 ± 4
GBM cells acutely dissociated from patients were treated for 5 days with TMZ and TMZ/TRAM-34 (T+T) and analyzed for 
viability by MTT assay. Results are expressed as viable cells in treated vs untreated samples (%). * p<0.05, ** p<0.01 vs C; 
# p<0.05, ##p<0.01, ###p<0.01 vs TMZ, One-Way ANOVA, Student-Newman-Keuls post-test analysis.
Abbreviation: KCa3.1, intermediate-conductance calcium-dependent potassium channel 1; TRAM-34, 1-[(2-chlorophenyl)
(diphenyl)methyl]-1H-pyrazole; GBM, glioblastoma multiforme; TMZ, temozolomide; DMEM, Dulbecco’s modified 
minimum essential medium; FBS, fetal bovine serum; MTT, 3-(4, 5-Dimethylthiazol-2-yl)- 2, 5-diphenyltetrazolium 
bromide; GFAP, glial fibrillary acidic protein; BSA, bovine serum albumin; HEPES, hydroxyethyl piperazineethanesulfonic 
acid; DMSO, dimethyl sulfoxide; PBS, potassium phosphate buffer; ANOVA, analysis of variance; SKA-31, naphtho 
[1, 2-d] thiazol-2-ylamine.
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stroke [26]. Glioma cells induce neuronal death through 
glutamate release in the extracellular space [28]. Here 
we show that TRAM-34 reduces GL261 cells-induced 
neuronal death in a co-culture system. Specific depletion 
of microglial cells from the hippocampal cultures with 
clodronate, abolished TRAM-34 induced neuronal 
protection, demonstrating a specific effect of KCa3.1 
expressed on microglia in reducing glioma-induced 
neuronal cell death. We have recently demonstrated that 
the blockade of KCa3.1 activity on microglia conditioned 
by glioma modifies their phenotype to a pro-inflammatory, 
anti-tumor state [40]. However, we cannot exclude that in 
Figure 7: TRAM-34/TMZ treatment decreases CSC proliferation. A. Representative morphology of GBM enriched CSC 
cultured as neurospheres. Magnification 10X. Scale bar 500 μm B. Time course of the effect of TRAM-34 (2.5 μM) on current evoked in 
GBM enriched CSC cells (n= 10) by repeated voltage ramps (from -130 mV to + 50 mV, holding potential -70 mV). Acute application 
of TRAM-34 revealed the functional expression of KCa3.1 channels. Typical current trace in response to repeated ramps is shown in the 
inset. C. CSC were treated for 4 days with TMZ, TRAM-34 or both (T+T) and analyzed for proliferation measured as [3H]-thymidine 
incorporation. Data are expressed as % of vehicle-treated cells (control, C); * p<0.05 vs C; ° p<0.05 vs TMZ n= 3, One-Way ANOVA, 
Student-Newman Keuls post-test.
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the tumor microenvironment this microglia phenotype also 
induces a direct protective effect on neurons [41].
Together, these data pave the road to the 
understanding of the molecular mechanisms involved in 
the increase of survival time in TMZ/TRAM-34 treated 
mice. In particular TRAM-34 increases TMZ mediated 
cytotoxicity, reduces tumor cell invasion, and reduces 
neuronal cell death induced by glioma (summarized in 
Supplementary Figure S5). Therefore, KCa3.1 inhibition 
in combination with TMZ may offer a new therapeutic 
approach for GBM patients. This approach is attractive 
since TMZ is the first line chemotherapeutic agent (and 
often the only one) used for this disease, and KCa3.1 
overexpression in patients correlates with a poor prognosis 
[10, 42, 43]. In addition the KCa3.1 blocker Senicapoc 
(ICA-17043), which is structurally related to TRAM-34, 
has already been used in clinical trials and has been found 
to be safe for patients [44, 45].
MATERIALS AND METHODS
Materials
Cell culture medium (Dulbecco’s modified 
minimum essential medium, DMEM), fetal bovine serum 
(FBS), penicillin G, streptomycin, glutamine, sodium 
pyruvate and Hoechst 33342 were from GIBCO Invitrogen 
(Carlsbad, CA); rabbit anti p-cdc2(Tyr15) was from 
Cell Signaling (Danvers, MA), mouse anti cdc2p34 and 
cyclin D1 were from Santa Cruz (Dallas, TX); Matrigel 
and Transwell inserts were from BD (Franklin Lakes, 
NJ); Encapsome and Clodrosome were from Encapsula 
NanoSciences (Nashville, TN); 3-(4, 5-Dimethylthiazol-2-
yl)- 2, 5-diphenyltetrazolium bromide (MTT) salt, DMSO, 
peanut oil, SKA-31, pLKO.1 lentiviral shRNA clones 
targeting human and murine KCa3.1 mRNA and all other 
chemicals were from Sigma-Aldrich (St. Louis, MO) or 
Pierce (Rockford, IL). TRAM-34 was synthesized in our 
lab as previously described [3]. NSC95397 was from Enzo 
Life Sciences, Inc. (New York, NY).
Experiments with animals
Experiments described in the present work were 
approved by the Italian Ministry of Health in accordance 
with the guidelines on the ethical use of animals from the 
European Community Council Directive of 22 September 
2010 (2010/63/EU). All efforts were made to minimize 
the number of animals used and their suffering. We used 
C57BL/6 mice from Charles River Laboratories.
Cell cultures
GL261 cells were kindly provided by Dr. Serena 
Pellegatta, Neurological Institute “Carlo Besta”, Italy. 
U87MG, GL261 and GL261-RFPcells (obtained as 
previously described, [46]) were cultured in DMEM 
supplemented with 10-20% heat-inactivated FBS, 100 
IU/ml penicillin G, 100 μg/ml streptomycin, 2.5 μg/ml 
amphotericin B, 2 mM glutamine, and 1 mM sodium 
pyruvate. Cells were grown at 37°C in a 5% CO
2
 
humidified atmosphere. Cells were subcultivated when 
confluent.
Human freshly dissected and primary GBM cells 
(GBM18) were obtained after patient surgery at Policlinico 
Umberto I (Rome) and Neuromed (Pozzilli, IS), from 
GBM patients who gave a written informed consent to 
the research proposals. The study was approved by the 
Institutional Ethics Committee of Sapienza University. 
Histopathological typing and tumor grading were done 
according to the WHO criteria resulting as grade IV. 
GBM cells from patients were obtained as described in our 
previous work [30]. After 10-15 days, adherent cells were 
sub-cultured once and then used for experiments. Freshly 
dissociated cell cultures were named as described in Table 
1. Primary GBM18 were obtained after further culturing 
adherent tumor cells and were used between passages 20 
and 30.
Cancer stem cells
Glioblastoma enriched CSC culture was established 
from freshly dissociated surgical specimen as previously 
described [47]. After three weeks, cells in suspension grew 
as neurospheres. For the experiments, the spheres were 
dissociated to single cells suspension, for no more than 
three times.
Glioma cell treatments
Before treatments, cells were shifted to culture 
medium containing 1% FBS, vehicle (DMSO), TMZ (30 
μΜ), TRAM-34 (5 μM) or both. The TMZ concentration 
was chosen considering the levels reported for patients 
treated with standard therapy [48–50]. The TRAM-34 
concentration was chosen based on previous experiments 
[11, 30] and based on test experiments (MTT proliferation 
assay) demonstrating that 5 μM TRAM-34 was necessary 
to increase TMZ effect (Supplementary Figure S6). Final 
DMSO concentration was always 0.08% (v/v). Incubation 
time was specified for each experiment.
Wound-healing assay
Cells (3.5 x104) were seeded and cultured into the 
inner wells of cell culture inserts (ibidi, Germany) and 
placed in a Petri dish. Once attached to the substratum, the 
inserts were removed from the surface leaving a 500 μm 
cell-free wound. To evaluate basal migration, the wounded 
areas were photographed at 0 and 48h with a CoolSNAP 
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camera (Photometrics) coupled to an ECLIPSE Ti-S phase 
contrast microscope (Nikon, Japan) and processed using 
MetaMorph 7.6.5.0 image analysis software (Molecular 
Device, CA). Wound healing was measured as follows: 
[1- (empty area at 48h/ empty area at 0h)] x100.
Transwell invasion assay
Sub-confluent GL261 cells were trypsinized, and 
plated in invasion medium (DMEM supplemented with 
100 IU/ml penicillin G and 100 μg/ml streptomycin, 
0.1% BSA and 25 mM HEPES, pH 7.4), at a density of 
7 x 103 cells/cm2 on matrigel-coated transwells (Corning, 
8 μm pore size). Cells were treated and incubated for 48 
h at 37°C, then fixed in ice-cold 10% trichloroacetic acid 
for 10 min. Cells adhering to the upper side of the filter 
were scraped off, whereas cells invaded through the insert 
were stained with a solution containing 50% isopropanol, 
1% formic acid and 0.5% (w/vol) brilliant blue R 250 
(Sigma-Aldrich) and counted in at least 20 fields with a 
20x objective.
Colony forming assay
GL261 cells were trypsinized, counted and 
plated (1 x 103) in 6 cm dishes containing 20% FBS 
medium. After 6h the growth medium was changed and 
supplemented with TRAM-34 or TMZ for 24h. Every 
three days the medium was changed and only TRAM-34 
was refreshed; 14 days after plating cells were fixed in 4% 
p-formaldehyde in PBS and stained with cresyl violet for 
20 min. Only colonies containing more than 50 cells were 
scored as positive.
Glutamate release
Glutamate concentration was determined in cellular 
supernatant by reversed-phase High Performance Liquid 
Chromatography (HPLC) following Dabsyl Chloride 
derivatization [51].
Protein preparation and western blot analysis
For protein analysis, 5 x 105 GL261 cells were 
seeded on 12 well plates and treated with vehicle, TMZ, 
TRAM-34 or both for 48h; cells were washed with PBS 
and lysed in hot 2x Laemmli buffer, boiled 5 min and 
sonicated. The same amount of proteins was separated on 
12% SDS-polyacrylamide gel and analyzed by Western 
immunoblot using the following primary antibodies: 
cyclin D1 1:200, p-cdc2 (Tyr15) 1:1000, cdc2p34 
1:200. HRP-tagged goat anti-rabbit and anti mouse-IgG 
were used as secondary antibodies (1:2000; Dako), and 
detection was performed by the chemiluminescent assay 
Immun-Star WesternC Kit (Bio-Rad, CA). Densitometric 
analysis has been carried out with Quantity One software 
(Biorad, CA).
Primary hippocampal neuronal cultures
Primary hippocampal neuronal cultures were 
prepared from 0-2-day old (p0–p2) C57BL/6 mice. Briefly, 
after careful dissection from diencephalic structures, the 
meninges were removed and hippocampal tissues chopped 
and digested for 20 min at 37 °C in 0.025% trypsin 
and Hank’s balanced salt solution (HBSS). Cells were 
washed twice with HBSS to remove the excess of trypsin, 
mechanically dissociated in minimal essential medium 
(MEM) with Earl’s Salts and GLUTAMAX supplemented 
with 10% dialyzed and heat inactivated FBS. Cells were 
plated at a density of 2 x 105 in the same medium on poly-
L-lysine- (100 μg/ml) coated plastic 24-well dishes. After 
2h, the medium was replaced with serum- free Neurobasal/
B27. Cells were kept at 37 °C in 5% CO2 for 11 days. 
With this method we obtained 60-70% neurons, 30-35% 
astrocytes, 4-8% microglia, as determined with β-tubulin 
III, GFAP, and IBA-I staining [52].
Neurons/GL261-RFP co-cultures
Primary hippocampal neuronal cultures, at the 9th 
day in culture, were treated with empty or clodronate 
encapsulating liposomes (Cl
2
MBP) [52] to deplete 
microglial cells. After 24h, cells were co-cultured with 
or without GL261-RFP (8 x 105), for 18h on 6.5mm 
transwells (Corning, 0.4 μm pore size).
Neuronal viability assay
To evaluate neuron viability, hippocampal neuronal 
cultures were treated with detergent-containing buffer 
(0.05% ethyl hexadecyl dimethylammonium bromide, 
0.028% acetic acid, 0.05% Triton X-100, 0.3 mM NaCl, 
0.2 mM MgCl2, in PBS pH 7.4) and viable nuclei counted 
in a hemacytometer as described [53, 54]. Neuronal 
viability was also evaluated by MTT assay.
Growth curves, cell cycle analysis and apoptosis
GL261 cells (3.5 x104) were seeded into 12-well 
plates in triplicates and after 6h treated with TRAM-34, 
TMZ or both. For growth curves, after 1-4 days, cells were 
rinsed twice with PBS, fixed for 15 min in PFA 4% and 
stained with 0.1% crystal violet. Acetic acid (10%) was 
used to dissolve the stain. Absorbance was measured at 
590 nm and results were expressed as mean optical density 
(OD) ± SE. For cell cycle analysis, GL261 cells were 
harvested with trypsin-EDTA, washed with cold PBS, 
fixed in 70% ethanol for 1 h at 4°C and stained with 50 
μg/ml propidium iodide (PI) supplemented with 250 μg/ml 
RNase A for 30 min at RT in the dark. DNA content was 
measured using a FACSCalibur (BD Biosciences, NJ). For 
the detection of apoptosis, cells were harvested, washed 
with Binding Buffer (10 mM HEPES, 140 mM NaCl, 
and 2.5 mM CaCl
2
), and resuspended in FITC-conjugated 
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Annexin V (Bender MedSystems, Austria). After 15 min 
of incubation at RT, PI was added, and the percentage 
of AnnexinV-FITC and Annexin V-FITC/PI+ cells was 
determined.
KCa3.1 silencing by lentiviral transduction of 
shRNA constructs
GL261, U87MG and primary GBM18 cells 
were infected by lentivirus directing IPTG-inducible 
expression of KCa3.1 shRNA. Cells (1.6 x 104) were 
plated in 96-well plates and infected for 24 h according 
to the manufacturer’s instructions. Transduced cells 
were selected with 2.5 μg/ml puromycin for 3–12 days. 
IPTG (5 mM) was added to culture medium to induce 
shRNA expression. Knockdown efficiency of KCa3.1 
channels was evaluated by real time PCR (RT-PCR) and 
electrophysiological recordings. Cells were then named 
GL261shRNA, U87MGshRNA and GBM18shRNA.
Real time PCR
GL261shRNA, U87MGshRNA and GBM18shRNA 
cells (7 x 105) were induced with 5 mM IPTG or vehicle 
for 5 days. Total RNA was extracted by Trizol reagent 
(Invitrogen), quantified using the Ultraspec 2000 UV/
Visible (Pharmacia Biotech) and the reverse transcription 
reaction was performed in a thermocycler (MJ Mini 
Personal Thermal Cycler; Biorad) using IScriptTM 
Reverse Transcription Supermix (Biorad) according to 
the manufacturer’s protocol. RT-PCR was carried out 
in a I-Cycler IQ Multicolor RT-PCR Detection System 
(Biorad) using Sso Fast Eva Green Supermix (Biorad) 
according to the manufacturer’s instructions. The PCR 
protocol consisted of 40 cycles of denaturation at 95°C 
for 30 s and annealing/extension at 58°C for 30 s. For 
quantification analysis the comparative Threshold Cycle 
(Ct) method was used. The Ct values from each gene were 
normalized to the Ct value of GAPDH in the same RNA 
samples. Relative quantification was performed using the 
2-ΔΔCt method and expressed as fold increase in arbitrary 
values. Primer sequences for genes are: mouse gapdh 
forward 5’-3’ TCGTCCCGTAGACAAAATGG, reverse 
3’-5’ TTGAGGTCAATGAAGGGGTC; human GAPDH 
5’-3’ forward CCCCTTCATTGACCTCAACTAC; 5’-3’ 
reverse GATGACAAGCTTCCCGTTCTC; mouse kcnn4 
forward 5’-3’ GGCTGAAACACCGGAAGCTC reverse 
3’-5’ CAGCTCTGTCAGGGCATCCA; human KCNN4 
forward 5’-3’ GGCTGAAACACCGGAAGCTC reverse 
3’-5’ CAGCTCTGTCAGGGCATCCA.
MTT cell viability assay
Acutely isolated GBM cells, GBM and glioma cell 
lines, and silenced cells were seeded into multi-well plates 
and treated with vehicle (C), TMZ, TRAM-34 or TMZ/
TRAM-34 for 4 or 5 days. MTT (500 μg/ml) was added 
into each well for 1.5 h. DMSO was then added to stop 
the reaction and the formazan produced was measured 
at 570 nm. Viability of cells was expressed relative to 
absorbance.
[3H]-Thymidine incorporation assay
GBM enriched CSCs (500 cells/well) were seeded 
in 96-well round-bottomed microtest culture plates and 
treated with vehicle, TRAM-34, TMZ or both. After 
4 days of incubation, cells were pulsed with 1μCi of 
[3H]-thymidine per well for the last 18 h, harvested and 
counted. Tests were performed in triplicate and results 
were expressed as the percentage of vehicle treated cells.
Intracranial inoculation
Eight week-old male mice were anesthetized 
with chloral hydrate (400 mg/kg, i.p.) and placed in a 
stereotaxic head frame. Animals were injected with 1 x 105 
GL26-RFP cells: a median incision of ~1 cm was made, a 
burr hole was drilled in the skull, and cells were injected in 
the right striatum (-2 mm lateral, +1 mm antero-posterior 
from Bregma). Cell suspension in PBS (5 μl) was injected 
with a Hamilton syringe at a rate of 1 μl/min at 3 mm 
depth. After 7 days mice were treated with TRAM-34 (120 
mg/kg/daily i.p. in peanut oil), TMZ (50 mg/kg i.p. every 
two days for four times with two weeks stop) or both. 
After 21 days or at moribund state, mice were sacrificed. 
The 21 day period was necessary to complete a TMZ 
cycle. Animals used in Kaplan-Meier survival studies 
received up to four TMZ cycles.
Tumor volume measurement and 
immunostaining
Brains were isolated and fixed in 4% buffered 
p-formaldehyde 21 days after GL261-RFP injection. 
Coronal brain sections (20 μm) were prepared by standard 
procedures and stained with hematoxylin and eosin. A 
section every 80 μm was collected, and the tumor volume 
was evaluated using Image Tool 3.00. To detect apoptosis, 
parallel serial brain sections were washed in PBS, blocked 
(3 % goat serum in 0.03 % Triton X-100) for 1 h at RT, 
and incubated overnight at 4 °C with FITC-conjugated 
Annexin V. Apoptosis was measured under a fluorescence 
microscope as the area occupied by Annexin V-positive 
cells versus the analyzed area; this pixel-based method 
was chosen to evaluate the scattered Annexin V signal. At 
least 6 coronal sections per brain were analyzed.
Patch-clamp experiments
Cells (GL261, U87MG, GBM18, CSC, 
GL261shRNA) were patched in the whole-cell 
Oncotarget14www.impactjournals.com/oncotarget
configuration. Micropipettes (4–5 MΩ) were filled 
with an intracellular solution containing the following 
(in mM): K-Asp 145, MgCl
2
 2, HEPES 10, EGTA 10, 
CaCl
2
 (3 μM free Ca2+, calculated using the MaxChelator 
software: http://www.stanford.edu/~cpatton/maxc.html, 
pH 7.3 adjusted with KOH, osmolarity 290 mOsm; 
Sigma Aldrich). During experiments, glioma cells were 
continuously superfused with an extracellular solution 





 1, HEPES 10 (pH 7.3), using 
a valve-controlled gravity driven perfusion system (VC-
6 Warner Instruments) connected to a perfusion pencil 
multi-barrel manifold tip (100 μM diameter, Automate 
Scientific), for standard and antagonist-containing 
solutions. All recordings were performed at 24–25 °C. 
Voltage-clamp recordings were carried out using an 
Axopatch 200B amplifier (Molecular Devices). Currents 
were filtered at 2 kHz, digitized (10 kHz) and collected 
using Clampex 10 (Molecular Devices); the analysis 
was performed off-line using Clampfit 10 (Molecular 
Devices). The current/voltage (I/V) relationship of each 
cell was determined applying voltage ramps from -130 to 
+50 mV for 200 ms; the holding potential was -70 mV 
between ramps. KCa3.1 current expression was evaluated 
using TRAM-34 (2.5 μM, 8 min); in particular, it was the 
result of the algebraic subtraction of the current obtained 
after TRAM-34 application, from the control current. 
As glioma cells display a prominent Kv current, all 
experiments were performed in the presence of the Kv1.3 
blocker PAP-1 (1 μM).
Statistics
All data shown as mean values with standard 
errors were analyzed with One Way ANOVA by Student-
Newman-Keuls post test. Mouse survival was compared 
between groups with the Kaplan-Meier survival analysis 
with log-rank test.
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